Irinotecan's Power With Fewer Side Effects: Cancer Treatment With Nanotechnology-Based DEP-SN38

New Horizons in Nanotechnology and Cancer Treatment

Nanotechnologyinvolves controlling and designing matter at the nanometer scale (a billionth of a meter) . At this scale, drugs can be reengineered using special delivery systems to reach targeted tissues directly.

In cancer treatment, conventional chemotherapy drugs generally affect both tumor cells and healthy cells. This limits efficacy and causes side effects such as nausea, vomiting, diarrhea, hair loss, and bone marrow suppression. Nanotechnology approaches aim to overcome this problem in three main ways:

• Directing the drug to tumor tissue,
• Increasing efficacy,
• Minimizing side effects.

Summary: Nanotechnology prolongs a drug's circulation, enables selective tumor delivery and controlled release, and thus widens the therapeutic window .

One of the first major examples of nanotechnology entering clinical practice is a formulation in which paclitaxel is bound to albumin nanoparticles , called nab-paclitaxel (Abraxane) .

• FDA approval: 2005; breast, pancreatic, and lung cancer treatment uses.
• Clinical advantage: Compared with conventional paclitaxel, less solvent is required ⇒ lower risk of severe allergic reactions; drug delivery to the tumor is facilitated.

A contemporary example of nanotechnology is liposomal irinotecan (Onivyde) .

• FDA approval: 2015; metastatic pancreatic cancerafter gemcitabine—an important option.
• Mechanism: The liposomal structure keeps irinotecan in circulation longerand increases delivery of the active metabolite SN38 to the tumor ⇒ potential for improved efficacy.

Irinotecanis an effective chemotherapy agent used in many tumors, particularly colorectal cancer. However, alongside its efficacy, two critical side effects can complicate clinical practice: neutropenia and late-onset diarrhea. These toxicities are major limiting factors affecting both patient safety and treatment continuity.

🔬 Mechanism 1: Neutropenia

• Irinotecan → SN38 (active metabolite)
  SN38 formed in the liver provides the main tumor-killing effect.
• SN38 → SN38-glucuronide (SN38G)
  This conversion occurs through the UGT1A1 enzyme . SN38G is less toxic and is excreted in urine.
• If UGT1A1 activity is low, SN38 cannot be adequately detoxified → SN38 accumulates in the blood → particularly causing neutropenia .

💡 Therefore, UGT1A1 genetic testingis used to predict irinotecan toxicity.

• Risk is particularly high in people with the UGT1A1 *28/*28 or *6/*6 polymorphism.
• The FDA recommends genotyping before starting irinotecan, particularly when high doses are planned.

🔬 Mechanism 2: Diarrhea

⚡ Early-Onset Diarrhea (<24 hours)

• Irinotecan inhibits acetylcholinesterase, causing cholinergic syndrome .
• This presentation may have diarrhea, abdominal cramps, sweating, salivation, rhinorrhea, and bradycardia as accompanying features.
• It is usually rapidly controlled with atropin treatment.

🐛 Late-Onset Diarrhea (≥24 hours)

• Irinotecan's active metabolite SN-38undergoes glucuronidation in the liver by the UGT1A1 enzyme → SN-38 glucuronide (SN38G) is formed.
• SN38G is normally less toxic and is excreted through bile and urine.
• However, intestinal bacterial β-glucuronidase enzymesconvert SN38G back to SN-38.
• The resulting active SN-38 damages the intestinal mucosa → severe delayed diarrhea may develop.

❓ Why Is It More Severe in Some People?

• Genetic differences: People with UGT1A1*28 or similar polymorphisms have reduced capacity to glucuronidate SN-38. Through bile, the intestines receive → more active SN-38 → more severe toxicity.
• Microbiota differences: The abundance of β-glucuronidase-producing gut bacteria varies between people. With high enzyme activity, more SN-38 is reactivated.
• Dose and concomitant treatments: High irinotecan doses, antibiotic use (altering the microbiota), or concomitant medications may increase diarrhea severity.

👉 In summary: Early diarrhea develops through a cholinergic mechanism, whereas late diarrhea depends on microbiota and UGT1A1 metabolism . Severe delayed diarrhea results from combined genetic and microbial factors.

🧪 Can Testing Predict It?

• For neutropenia:
  • UGT1A1 genetic testing ✔️ — The FDA recommends irinotecan dose reduction, particularly in UGT1A1*28 homozygous individuals.
  • This test is available in clinical practice and predicts the risk of serious hematologic toxicity (particularly neutropenia) .
• For diarrhea:
  • Late diarrhea is primarily associated with intestinal bacterial β-glucuronidase activity .
  • This mechanism is microbiota-dependent, rather than pharmacogenetic; UGT1A1 testing therefore does not predict diarrhea risk.
  • There is no routine clinical test ❌for intestinal β-glucuronidase activity; stool enzyme measurements or microbiota analyses are available only in research.
  • Because diarrhea risk cannot be predicted clinically, close monitoring and a high-dose loperamide protocol are standard.

Note: DEP-SN38 aims, by bypassing individual variation in irinotecan-SN38 conversion, to improve tumor localization and tolerability .

💡 Note: At this point, dendrimer-based nanoparticle technology used to develop DEP-SN38could open a new chapter in cancer treatment.

👉 This approach could overcome chemotherapy's “effective but intolerable” paradox.

👉 These results strongly show DEP-SN38 is safer than irinotecan .